IKNA - Ikena Oncology - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-66.53M

Cash

157.3M

Avg Qtr Burn

-19.57M

Short % of Float

2.80%

Insider Ownership

7.00%

Institutional Own.

92.32%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IK-175 (AHR Inhibitor) Details Bladder cancer, Solid tumor/s, Cancer, Urothelial carcinoma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IK-595 (MEK-RAF Molecular Glue) Details Cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IK-930 (TEAD1) Details Cancer, Solid tumor/s, Non-small cell lung carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IK-007 Details Solid tumor/s, Colorectal cancer , Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.